Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · IEX Real-Time Price · USD
0.363
-0.007 (-1.87%)
Apr 19, 2024, 11:13 AM EDT - Market open
Company Description
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics.
The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine.
The company is headquartered in Toronto, Canada.
Cybin Inc.
| Country | Canada |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Douglas L. Drysdale |
Contact Details
Address: 100 King Street West, Suite 5600 Toronto, A6 M5X 1C9 Ontario, Canada | |
| Phone | (908) 764-8385 |
| Website | cybin.com |
Stock Details
| Ticker Symbol | CYBN |
| Exchange | NYSEAMERICAN |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001833141 |
| CUSIP Number | 23256X100 |
| ISIN Number | CA23256X1006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric So L.L.B. | Co-Founder, President and Executive Chairman |
| Douglas L. Drysdale | Chief Executive Officer |
| Paul Glavine | Co-Founder, Chief Growth Officer and Director |
| Greg Cavers | Chief Financial Officer |
| Aaron Bartlone | Chief Operating Officer |
| John Kanakis | Co-Founder |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Lori Challenger | Chief Compliance, Ethics and Administrative Officer |
| Gabriel Fahel | Chief Legal Officer and Corporate Secretary |
| Sara Brittany Somerset | Chief Communications Officers |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 6-K | Report of foreign issuer |
| Apr 18, 2024 | 6-K | Report of foreign issuer |
| Apr 18, 2024 | SUPPL | Filing |
| Apr 16, 2024 | 6-K | Report of foreign issuer |
| Apr 11, 2024 | F-10POS | Filing |
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 3, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 22, 2024 | 6-K | Report of foreign issuer |